PMID- 36705419
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230215
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 11
IP  - 1
DP  - 2023 Jan
TI  - Angiotensin converting enzyme 2 activation improves allergic rhinitis and 
      suppresses Th2 cytokine release.
PG  - e763
LID - 10.1002/iid3.763 [doi]
LID - e763
AB  - OBJECTIVE: Allergic rhinitis (AR) is primarily regulated by type I 
      hypersensitivity, with Th2 and immunoglobulin E (IgE) playing essential roles. 
      This study aimed to determine whether angiotensin converting enzyme (ACE)2 could 
      participate in the regulation of AR. METHODS: Nasal mucosal tissues of AR 
      patients were collected to determine ACE2 levels. Following AR mouse models were 
      established, ACE2 levels in nasal mucosa were determined. Then the influences of 
      diminazene aceturate (ACE2 agonist) on AR symptoms, pathology, specific 
      antibodies, histamine, and interleukins (ILs) release in vivo were evaluated. 
      Afterward, human nasal mucosa epithelial cells were exposed to IL-13, and the 
      impacts of ACE2 overexpression on the secretion of pro-inflammatory factors in 
      vitro were assessed. RESULTS: ACE2 levels significantly declined in nasal mucosa 
      both in patients and mouse models (p < .001). Diminazene aceturate treatment 
      elevated the ACE2 level in mice (p < .01), accompanied by reduced frequency of 
      nasal spray and nasal friction, decreased eosinophils and goblet cells (p < .001) 
      according to histopathological staining. Furthermore, lgE, lgG1, histamine, and 
      IL levels in mice were also decreased (p < .05). In vitro experiments revealed 
      that ACE2 overexpression suppressed the secretion of pro-inflammatory factors 
      (p < .001). CONCLUSION: Together, ACE2 activation can alleviate the symptoms of 
      AR in mice and inhibit the release of Th2 cytokines. Activating ACE2 is a 
      promising therapeutic approach for AR.
CI  - (c) 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Sun, Xiuying
AU  - Sun X
AUID- ORCID: 0000-0003-3388-444X
AD  - Department of Otorhinostomology, The Affiliated Huaian No. 1 People's Hospital of 
      Nanjing Medical University, Huai'an, Jiangsu, China.
FAU - Xu, Yu
AU  - Xu Y
AD  - Department of Otorhinostomology, The Affiliated Huaian No. 1 People's Hospital of 
      Nanjing Medical University, Huai'an, Jiangsu, China.
FAU - Zhou, Jinhui
AU  - Zhou J
AD  - Department of Otorhinostomology, The Affiliated Huaian No. 1 People's Hospital of 
      Nanjing Medical University, Huai'an, Jiangsu, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
RN  - 0 (Cytokines)
RN  - JI8SAD85NO (diminazene aceturate)
RN  - 820484N8I3 (Histamine)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Ace2 protein, mouse)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - *Angiotensin-Converting Enzyme 2/metabolism
MH  - *Cytokines/metabolism
MH  - Histamine
MH  - *Rhinitis, Allergic/metabolism
MH  - Th2 Cells
PMC - PMC9846113
OTO - NOTNLM
OT  - ACE2
OT  - Th2
OT  - allergic rhinitis
OT  - interleukin
OT  - lgE
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/28 06:00
MHDA- 2023/01/31 06:00
PMCR- 2023/01/18
CRDT- 2023/01/27 08:23
PHST- 2022/11/29 00:00 [revised]
PHST- 2022/10/18 00:00 [received]
PHST- 2022/12/29 00:00 [accepted]
PHST- 2023/01/27 08:23 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2023/01/18 00:00 [pmc-release]
AID - IID3763 [pii]
AID - 10.1002/iid3.763 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2023 Jan;11(1):e763. doi: 10.1002/iid3.763.